Te Ahumairangi Investment Management Ltd Acquires 26,834 Shares of Pfizer Inc. $PFE

Te Ahumairangi Investment Management Ltd grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 12.7% during the second quarter, Holdings Channel reports. The firm owned 237,946 shares of the biopharmaceutical company’s stock after purchasing an additional 26,834 shares during the period. Te Ahumairangi Investment Management Ltd’s holdings in Pfizer were worth $5,730,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Evolution Wealth Management Inc. increased its position in Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 566 shares during the last quarter. Godfrey Financial Associates Inc. acquired a new stake in shares of Pfizer in the fourth quarter worth about $26,000. Keb Asset Management LLC bought a new stake in shares of Pfizer during the 2nd quarter worth about $26,000. HFM Investment Advisors LLC increased its holdings in shares of Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 427 shares during the last quarter. Finally, Global Trust Asset Management LLC raised its stake in shares of Pfizer by 126.7% in the 1st quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 650 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of NYSE:PFE opened at $27.97 on Tuesday. The business has a 50 day moving average price of $25.34 and a 200 day moving average price of $26.26. Pfizer Inc. has a twelve month low of $23.58 and a twelve month high of $28.75. The company has a market cap of $159.41 billion, a price-to-earnings ratio of 36.80 and a beta of 0.34. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The company had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the previous year, the business posted $0.78 EPS. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts predict that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.1%. Pfizer’s payout ratio is 226.32%.

Analyst Ratings Changes

Several equities research analysts recently weighed in on PFE shares. UBS Group restated a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a report on Wednesday, May 27th. BMO Capital Markets lowered their price target on Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a report on Monday, July 13th. Citigroup lifted their price target on shares of Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research report on Wednesday, April 29th. JPMorgan Chase & Co. reduced their price objective on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a research note on Wednesday, July 8th. Finally, HSBC downgraded shares of Pfizer from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $32.00 to $28.00 in a report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Pfizer presently has a consensus rating of “Hold” and an average price target of $28.28.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.